Fortress Biotech (STU:CNB1) Research & Development: €7.38 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CNB1 Fortress Biotech Inc STU:CNB1
46 GF Score
Price €1.93
GF Value €0.68
! 7 Warning Signs
View Full Analysis

What is Fortress Biotech Research & Development?

Fortress Biotech STU:CNB1 46 Research & Development is €7.38 Mil as of Mar. 2026. GuruFocus rates STU:CNB1 with a GF Score™ of 46/100 and a GF Value™ of €0.68. The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Fortress Biotech's Research & Development for the three months ended in Mar. 2026 was €0.47 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €7.38 Mil.

Fortress Biotech  (STU:CNB1) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Fortress Biotech Research & Development Related Terms

Fortress Biotech Research & Development Historical Data

* Premium members only.

The historical data trend for Fortress Biotech's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fortress Biotech Research & Development Chart

Fortress Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 114.05 127.32 97.27 54.32 10.16

Fortress Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.64 7.05 0.18 -0.31 0.47
STU:CNB1
46GF Score
Fortress Biotech Inc STU:CNB1
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fortress Biotech Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €7.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €7.38 Mil mean?
Fortress Biotech (STU:CNB1) has a Research & Development of €7.38 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Fortress Biotech and its competitors.
Is Fortress Biotech's Research & Development too high?
Fortress Biotech's current Research & Development is €7.38 Mil. Overall, Fortress Biotech has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Fortress Biotech's Research & Development compare to RLYB and INO?
Fortress Biotech's Research & Development of €7.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Fortress Biotech and its competitors. Fortress Biotech's current Research & Development is €7.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortress Biotech stock overvalued right now?
Fortress Biotech (STU:CNB1) has a current Research & Development of €7.38 Mil. The stock's GF Value™ is €0.68, compared to a current price of €1.93 — trading 183.8% above its estimated fair value. The current Research & Development is €7.38 Mil. Fortress Biotech's overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Fortress Biotech (STU:CNB1), the current Research & Development is €7.38 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fortress Biotech (STU:CNB1) Overvalued in 2026?

Based on GuruFocus' analysis, Fortress Biotech stock appears to be overvalued. The current stock price of €1.93 is trading 183.8% above its estimated GF Value™ of €0.68.

Key valuation signals for STU:CNB1:

  • Research & Development: €7.38 Mil
  • GF Value™: €0.68 vs. price of €1.93 (183.8% above fair value)
  • GF Score™: 46/100 with 7 warning signs

No single metric tells the full story. See the STU:CNB1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fortress Biotech Business Description

Address 1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
46GF Score

Get the complete analysis for STU:CNB1

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.93
Price
€0.68
GF Value